Antares Pharma Inc (ATRS):企業の財務・戦略的SWOT分析

◆英語タイトル:Antares Pharma Inc (ATRS) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15775
◆発行会社(調査会社):GlobalData
◆発行日:2019年4月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Antares Pharma Inc (ATRS) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Antares Pharma Inc (Antares Pharma) is a specialty pharmaceutical company that develops, manufactures, and commercializes self-administered parenteral pharmaceuticals and drug delivery systems and technologies. The company’s portfolio encompasses novel therapeutic products for the treatment of polyarticular juvenile idiopathic arthritis, and adults with severe rheumatoid arthritis, severe recalcitrant psoriasis, migraine and cluster headache, and to reduce the risk of preterm birth in pregnant women. It caters its subcutaneous injection technology platforms to both generic and branded injectables. Antares Pharma’s injectables are available in disposable multi-dose pen injectors and unit dose containers. The company employs its drug delivery systems to advance drug compounds and drug delivery methods. It also advances various product development programs in partnership with various leading pharmaceutical companies including Teva and AMAG. The company has a presence in the US and Switzerland. Antares Pharma is headquartered in Ewing, New Jersey, the US.

Antares Pharma Inc Key Recent Developments

Mar 06,2019 Antares Pharma to Present at the Cowen and Company 39th Annual Healthcare Conference
Mar 04,2019 Antares Pharma announces board changes
Feb 28,2019 Antares Pharma Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
Dec 13,2018 Antares Pharma names Peter S. Greenleaf to company’s Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Antares Pharma Inc – Key Facts
Antares Pharma Inc – Key Employees
Antares Pharma Inc – Key Employee Biographies
Antares Pharma Inc – Major Products and Services
Antares Pharma Inc – History
Antares Pharma Inc – Company Statement
Antares Pharma Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Antares Pharma Inc – Business Description
Geographical Segment: Europe
Performance
Geographical Segment: Other
Performance
Geographical Segment: The US
Performance
R&D Overview
Antares Pharma Inc – SWOT Analysis
SWOT Analysis – Overview
Antares Pharma Inc – Strengths
Antares Pharma Inc – Weaknesses
Antares Pharma Inc – Opportunities
Antares Pharma Inc – Threats
Antares Pharma Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Antares Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Antares Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Antares Pharma Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 06, 2019: Antares Pharma to Present at the Cowen and Company 39th Annual Healthcare Conference
Mar 04, 2019: Antares Pharma announces board changes
Feb 28, 2019: Antares Pharma Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
Dec 13, 2018: Antares Pharma names Peter S. Greenleaf to company’s Board of Directors
Dec 13, 2018: Antares Pharma announces the appointment of Peter S. Greenleaf to Company’s Board of Directors
Sep 17, 2018: Antares Supports Quad-C Management’s Acquisition of NJRetina
Aug 07, 2018: Antares Pharma Reports Second Quarter 2018 Operating and Financial Results
Aug 06, 2018: Antares Pharma names Dr. James Tursi executive vice president, head of research & development, chief medical officer
May 08, 2018: Antares Pharma Reports First Quarter 2018 Operating and Financial Results
Mar 13, 2018: Antares Pharma reports fourth quarter and full year 2017 operating and financial results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Antares Pharma Inc, Key Facts
Antares Pharma Inc, Key Employees
Antares Pharma Inc, Key Employee Biographies
Antares Pharma Inc, Major Products and Services
Antares Pharma Inc, History
Antares Pharma Inc, Other Locations
Antares Pharma Inc, Subsidiaries
Antares Pharma Inc, Key Competitors
Antares Pharma Inc, Ratios based on current share price
Antares Pharma Inc, Annual Ratios
Antares Pharma Inc, Annual Ratios (Cont...1)
Antares Pharma Inc, Interim Ratios
Antares Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Antares Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Antares Pharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Antares Pharma Inc, Performance Chart (2014 - 2018)
Antares Pharma Inc, Ratio Charts
Antares Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Antares Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Antares Pharma Inc (ATRS):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Toyo Seikan Group Holdings, Ltd.:企業の戦略・SWOT・財務分析
    Toyo Seikan Group Holdings, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Toyo Seikan Group Holdings, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Global Telecom Holding SAE:企業の戦略的SWOT分析
    Global Telecom Holding SAE - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Norgine BV:医療機器:M&Aディール及び事業提携情報
    Summary Norgine BV (Norgine) is a pharmaceutical company that offers medicinal products. The company develops drugs in the therapeutic areas of gastroenterology, incontinence, hepatology and critical and supportive care and pain management, among others. It offers the treatment of diseases related t …
  • Kimal plc-医療機器分野:企業M&A・提携分析
    Summary Kimal plc (Kimal) is a medical equipment company that develops, manufactures and markets customised procedure packs and vascular access devices. The company’s products include soft tissue biopsy needles, bone marrow biopsy needles, catheter accessories, catheter lock solution, closure device …
  • Roswell Park Cancer Institute-製薬・医療分野:企業M&A・提携分析
    Summary Roswell Park Cancer Institute (RPCI) is a cancer treatment institute that provides diagnosis, treatments and services for various kinds of cancer. The institute’s treatment includes advanced endoscopy, BMT, interventional pulmonology, interventional radiology, anesthesiologists, psychologist …
  • China Agri-Industries Holdings Ltd (606):企業の財務・戦略的SWOT分析
    China Agri-Industries Holdings Ltd (606) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Zimplats Holdings Ltd:企業の戦略・SWOT・財務情報
    Zimplats Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Zimplats Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Kansai Paint Co Ltd (4613):企業の財務・戦略的SWOT分析
    Kansai Paint Co Ltd (4613) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Eastman Chemical Company:企業のM&A・事業提携・投資動向
    Eastman Chemical Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Eastman Chemical Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Neovasc Inc (NVCN)-医療機器分野:企業M&A・提携分析
    Summary Neovasc Inc (Neovasc) is a medical device company that develops, manufactures and sells products for cardiovascular disease. The company offers products such as tiara, reducer and tissue products. Its tiara is a novel transcatheter device that is designed for treating mitral regurgitation, a …
  • Neiman Marcus Group LTD LLC:戦略・SWOT・企業財務分析
    Neiman Marcus Group LTD LLC - Strategy, SWOT and Corporate Finance Report Summary Neiman Marcus Group LTD LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Butler National Corporation:企業の戦略・SWOT・財務分析
    Butler National Corporation - Strategy, SWOT and Corporate Finance Report Summary Butler National Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Rite Aid Corp (RAD)-製薬・医療分野:企業M&A・提携分析
    Summary Rite Aid Corp (Rite Aid) is retail drugstore chain. The company sells prescription drugs and a wide range of other merchandise such as, over-the-counter (OTC) medications, personal care items, health and beauty aids, cosmetics, household items, beverages, convenience foods, greeting cards, s …
  • Total SA (FP):企業の財務・戦略的SWOT分析
    Total SA (FP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • IHI Corporation:企業のM&A・事業提携・投資動向
    IHI Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's IHI Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Valio Ltd:企業の戦略的SWOT分析
    Valio Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Heidelberger Druckmaschinen AG:企業の戦略・SWOT・財務分析
    Heidelberger Druckmaschinen AG - Strategy, SWOT and Corporate Finance Report Summary Heidelberger Druckmaschinen AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Becton Dickinson and Co (BDX)-医療機器分野:企業M&A・提携分析
    Summary Becton Dickinson and Co (BD) is a medical technology company that manufactures and sells medical devices, reagents and instrument. Its major products include syringes and pen needles; intravenous catheters; infusion pumps and disposables; automated medication dispensing and supply management …
  • Celsion Corp (CLSN)-製薬・医療分野:企業M&A・提携分析
    Summary Celsion Corp (Celsion) is an oncology company that focuses on developing a portfolio of new cancer treatments, including directed chemotherapies, RNA based therapies and DNA-mediated immunotherapy. The company’s three platform technologies including Lysolipid Thermally Sensitive Liposomes (L …
  • Atox Bio Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Atox Bio Ltd (Atox Bio) is a late state biotechnology company that develops immunomodulators to treat critically ill patients with severe infections. The company develops drugs for patients suffering from necrotizing soft tissue infections, a flesh eating bacteria. It implements novel mode o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆